Selective IL-2 responsiveness of regulatory t cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes

Diabetes

Volumn 64, Issue 6, 2015, Pages 2172-2183

  Yu, Aixin ^a   Snowhite, Isaac ^a   Vendrame, Francesco ^a   Rosenzwajg, Michelle ^b,c,d   Klatzmann, David ^b,c,d   Pugliese, Alberto ^a   Malek, Thomas R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Unit of Dermatology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR GAMMA; MESSENGER RNA; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DOSE RESPONSE; EFFECTOR CELL; FEMALE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MALE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; CELL CULTURE; DIABETES MELLITUS, TYPE 1; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84928586624     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1322     Document Type: Article

References (34)

1. Malek TR, Castro I. Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 2010;33:153-165.
2. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871-1878.
3. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin- 2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28:687-697.
4. Webster KE, Walters S, Kohler RE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long- Term acceptance of islet allografts without immunosuppression. J Exp Med 2009;206:751-760.
5. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009;30:204-217.
6. + T centralmemory cell survival but not T effector-memory cell development. J Immunol 2011;187:5170-5182.
7. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007;39:1074-1082.
8. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010;59:407-415.
9. +) T cells. Genes Immun 2011;12:116-125.
10. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055-2066.
11. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to lowdose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-2077.
12. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013;5:179ra143.
13. Castela E, Le Duff F, Butori C, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol 2014;150:748-751.
14. Kennedy-Nasser AA, Ku S, Castillo-Caro P, et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 2014;20:2215-2225.
15. Hartemann A, Bensimon G, Payan CA, et al. Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomised, double-blind, placebocontrolled trial. Lancet Diabetes Endocrinol 2013;1:295-305.
16. + T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
17. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: An important NK cell subset. Immunology 2009;126:458- 465.
18. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its α, β, and gammac receptors. Science 2005;310:1159- 1163.
19. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998;70:1-81.
20. Ross JA, Cheng H, Nagy ZS, Frost JA, Kirken RA. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation. J Biol Chem 2010;285:3582-3591.
21. Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K. Functional domains of template- Activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun 1999;259:471-475.
22. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142- 1151.
23. + Tregs. J Clin Invest 2006;116:2521-2531.
24. Feinerman O, Jentsch G, Tkach KE, et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol Syst Biol 2010;6:437.
25. Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 2009;30:592-602.
26. Cohney SJ, Sanden D, Cacalano NA, et al. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol 1999;19:4980-4988.
27. Cornish AL, Chong MM, Davey GM, et al. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other γ c-dependent cytokines in peripheral T cells. J Biol Chem 2003;278:22755-22761.
28. Matsumoto A, Seki Y, Kubo M, et al. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 1999;19:6396-6407.
29. Sporri B, Kovanen PE, Sasaki A, Yoshimura A, Leonard WJ. JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood 2001;97: 221-226.
30. + regulatory T cells and SOCS3-mediated suppression of Treg function. Eur J Immunol 2007;37:2082-2089.
31. Tannahill GM, Elliott J, Barry AC, Hibbert L, Cacalano NA, Johnston JA. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 2005;25:9115-9126.
32. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009;30:80-91.
33. Long SA, Rieck M, Sanda S, et al.; Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012; 61:2340-2348.
34. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms. Diabetes 2013;62:2674-2682.